LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio response to NOU 2023 – 18 Gene technology in a sustainable future

22/02/2024

POLICY DOCUMENT

Brussels, 22 February 2024

EuropaBio welcomes the opportunity to comment on the Committee report Gene technology in a sustainable future. Our comments focus on the general principle of the majority’s proposal and on organisms intended for food, feed and agriculture, as well as other releases for industrial and environmental purposes (excluding GMO medicinal products).

EuropaBio considers that the Committee’s general assessment of the current situation is accurate: gene technology can contribute significantly to a more sustainable future; today’s regulations and their implementation create many obstacles to realise its full potential; current gene technology regulations, management and policies inhibit innovation and access to safe and useful products.

We fully agree with the recommendation of the Committee to modernise the current regulation of organisms and products developed using gene technology and advocate for similar modernisation of the EU GM framework. Furthermore, we also support the Committee’s view that any new proposal for regulating products developed with gene technology should consider all living organisms, i.e. plants, animals, and microorganisms. The scope of the proposal should be clear with regard to fermentation products: products produced using genetically modified microorganisms (GMMs) should not fall in scope of the Gene Technology Act.

See our comments in the document

EuropaBio response to NOU 2023 - 18 Gene technology in a sustainable future


Download

Share
Francesca Degli Agostini
Francesca Degli Agostini

Related posts

10/06/2025

EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union


Read more
10/06/2025

The EU economic and scientific future starts with the EU Biotech Act


Read more
30/05/2025

Open Letter of Business and Agri-Food Industry stakeholders on the need for a high-performing EFSA to boost the competitiveness of the EU agri-food sector


Read more

Important links

  • EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union
  • The EU economic and scientific future starts with the EU Biotech Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.